CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at $29.59 ($5,918,000)
- 4 Grant or award CFO acquired 60,644 shares (grant or award)
- 4 Grant or award Chief Accounting Officer acquired 29,173 shares (grant or award)
- 4 Shares withheld for taxes Director gave up 95 shares (to pay taxes)
- 4 Grant or award Director acquired 670 shares (grant or award)
- 4 Shares withheld for taxes Director gave up 94 shares (to pay taxes)
- 4 Open-market sale CEO sold 289,774 shares at $29.16 ($8,449,810)
- 144 Insider Sale of Securities
- 144/A Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Open-market sale Chief Accounting Officer sold 13,538 shares at $28.37 ($384,073)
- 144 Insider Sale of Securities
- 4 Shares withheld for taxes President and Vant Chair gave up 160,035 shares (to pay taxes)
- 8-K Event Results of operations · Regulation FD disclosure
- 4 Shares withheld for taxes CEO gave up 358,510 shares (to pay taxes)
Page 6 of 51 · 1,008 filings